| Biomarker ID | 770 |
| PMID | 21980368 |
| Year | 2011 |
| Biomarker | miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include (miR-126):- DNA-binding transcription factor activity, RNA polymerase II-specific; Gene expression (Transcription); RNA Polymerase II Transcription; Generic Transcription Pathway; nuclear chromatin Pathways Include (miR-144):- metal ion binding; cation binding;Gene expression (Transcription); Gene expression (Transcription); regulation of RNA metabolic process Pathways Include(miR-374a):- DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; nuclear chromosome; chromatin |
| Experiment | Metastatic Vs Non Metastatic |
| Type of Biomarker | Prognostic |
| Cohort | From 1 patient, metastatic versus a non-metastatic prostate cancer xenograft line were dervied. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | quantitative PCR (qPCR) |
| Clinical | No |
| Remarks | * indicates the less dominant arm in the miRNA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-7, miR-126, miR-144, miR-144*, miR-335*, miR-374a, miR-374a*, miR-28-3p, miR-542-3p |